International Journal of Medicine and Medical Sciences
Subscribe to IJMMS
Full Name*
Email Address*

Article Number - 2F77FC161333


Vol.8(11), pp. 120-124 , November 2016
DOI: 10.5897/IJMMS2016.1261
ISSN: 2006-9723



Full Length Research Paper

The use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of atrial fibrillation



Riyadh Mustafa Murtadha Al-Shehristani
  • Riyadh Mustafa Murtadha Al-Shehristani
  • University of Kerbala, Iraq.
  • Google Scholar







 Received: 12 August 2016  Accepted: 26 September 2016  Published: 30 November 2016

Copyright © 2016 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Atrial fibrillation is a common cardiac arrhythmia that has many risk factors including some medications; however, the effect of non-steroidal anti-inflammatory drugs (NSAIDs) and its risk is not well assessed. This study was conducted to find out if there is an association between the use of non-steroidal anti-inflammatory drugs and risk of atrial fibrillation. The study was conducted at Al-Hussein Medical City Hospital in Karbala-Iraq as a retrospective case-control study between September 2014 and March 2015; including 90 patients with atrial fibrillation and 90 control subjects who were age and sex matched, and based on risk-set sampling. Current use of NSAID was started within one month and chronic use for more than one month was recorded. The current use of NSAIDs by patients with atrial fibrillation was found in 43 patients out of 90 (47.7%) of which new users were 29 (32.2%) and chronic users were 14 (15.5%), while it was found in 27 out of 90 (30%) of the control subjects who were current users of NSAIDs. That difference was statistically significant (p-value was 0.015), the odds ratio (OR) was 2.135 and 95% confidence intervals (CI) was 1.16-3.94. This study suggests that the current use of NSAIDs might be associated with increased risk of incidence of atrial fibrillation.

Key words: Non-steroidal anti-inflammatory drugs, atrial fibrillation.

Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL (2001). Pathophysiology and prevention of atrial fibrillation. Circulation 103(5):769-777.
Crossref

 

Aw TJ, Haas SJ, Liew D, Krum H (2005). Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med. 165(5):490-496.
Crossref

 

Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG (2009). Prevention of atrial fibrillation. Report from a National Heart, Lung, and Blood Institute workshop. Circulation 119:606-618.
Crossref

 

De Caterina R, Ruigómez A, Rodríguez LA (2010). Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch. Intern. Med. 170:1450-1455.
Crossref

 

Engelmann MD, Svendsen JH (2005). Inflammation in the genesis and perpetuation of atrial fibrillation. Eur. Heart J. 26:2083-2092.
Crossref

 

Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF (1988). Obesity and knee osteoarthritis. The Framingham Study. Ann. Intern. Med. 109:18-24.
Crossref

 

Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Tarkington LG, Yancy CW (2011). ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation /American Heart Association Task Force on practice guidelines. Circulation 123:e269-367.
Crossref

 

Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC (2006). Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27:949-953.
Crossref

 

Holliday KL, McWilliams DF, Maciewicz RA, Muir KR, Zhang W, Doherty M (2011). Lifetime body mass index, other anthropometric measures of obesity and risk of knee or hip osteoarthritis in the GOAL case-control study. Osteoarthritis Cartilage 19:37-43.
Crossref

 

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A (2011). Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 123:1501-1508.
Crossref

 

Krijthe BP, Heeringa J, Hofman A, Franco OH, Stricker BH (2014). Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: a population-based follow-up study. BMJ Open. 4(4):e004059.
Crossref

 

Laine L (2002). The gastrointestinal effects of non-selective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 32:25-32.
Crossref

 

National Collaborating Centre for Chronic Conditions (UK) (2006). Atrial fibrillation: national clinical guideline for management in primary and secondary care. Royal College of Physicians.

 

Rosiak M, Dziuba M, Chudzik M, Cygankiewicz I, Bartczak K, Drozdz J, Wranicz JK (2010). Risk factors for atrial fibrillation: not always severe heart disease, not always so 'lonely'. Cardiol. J. 17(5):437-442.

 

Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT (2011). Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 343:d3450.
Crossref

 

Stevenson WG, Stevenson LW (2004). Atrial fibrillation and heart failure-five more years. N. Eng. J. Med. 351:2437-4240.
Crossref

 

Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086.
Crossref

 

Van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH (2004). Drug-induced atrial fibrillation. J. Am. Coll. Cardiol. 44:2117-2124.
Crossref

 

Whelton A (2001). Renal aspects of treatment with conventional non-steroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am. J. Med. 110:33S-42S.
Crossref

 

Wolf PA, Abbott RD, Kannel WB (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983-8.
Crossref

 

Zhang J, Ding EL, Song Y (2006). Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619-1632.
Crossref

 


APA Al-Shehristani, R. M. M. (2016). The use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of atrial fibrillation. International Journal of Medicine and Medical Sciences, 8(11), 120-124.
Chicago Riyadh Mustafa Murtadha Al-Shehristani. "The use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of atrial fibrillation." International Journal of Medicine and Medical Sciences 8, no. 11 (2016): 120-124.
MLA Riyadh Mustafa Murtadha Al-Shehristani. "The use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of atrial fibrillation." International Journal of Medicine and Medical Sciences 8.11 (2016): 120-124.
   
DOI 10.5897/IJMMS2016.1261
URL http://academicjournals.org/journal/IJMMS/article-abstract/2F77FC161333

Subscription Form